http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#Head http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#assertion http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#provenance http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#pubinfo http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#assertion http://purl.obolibrary.org/obo/DOID_3908 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3908 http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01229 http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association http://www.w3.org/2000/01/rdf-schema#label paclitaxel injection usp is indicated as first line and subsequent therapy for the treatment of advanced carcinoma of the ovary as first line therapy paclitaxel injection usp is indicated in combination with cisplatin paclitaxel injection usp is indicated for the adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicin containing combination chemotherapy in the clinical trial there was an overall favorable effect on disease free and overall survival in the total population of patients with receptor positive and receptor negative tumors but the benefit has been specifically demonstrated by available data median follow up 3 months only in the patients with estrogen and progesterone receptor negative tumors see clinical studies breast carcinoma paclitaxel injection usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy prior therapy should have included an anthracycline unless clinically contraindicated paclitaxel injection usp in combination with cisplatin is indicated for the first line treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and or radiation therapy paclitaxel injection usp is indicated for the second line treatment of aids related kaposi s sarcoma http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01229 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#provenance http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#pubinfo http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#sig http://purl.org/nanopub/x/hasSignature Pn2mLQBX5CCYVJBGpGNz8PGEnZjVVG7IoEZp4GWlrlFqkcB6+toC9oQmL4jOT4Xyn4TvzRg8wi+zVsoUuf32qdRv9EsieP8ml+IsOklcV5auol+W76paEAQz427cuTCaNHbruiaquQ8cZX7ohNOqLzILPJsijr7tunvN0/dGqEE= http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng http://purl.org/dc/terms/created 2021-06-27T20:16:36.924+02:00 http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAnoa3vYPn93obw9mQCWQOmkBuyZ2V52zVWA3iL66k6ng https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs